Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	DC	205/19
vvasiiiiiuluii.	D.C.	20349

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
obligations may continue. See		

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

0.5

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kirchgraber Paul R</u>					LA											all applic Directo	able)	g Pers	ion(s) to Issu 10% Ow Other (s	ner
(Last) 531 SOU	Last) (First) (Middle) 531 SOUTH SPRING STREET						3. Date of Earliest Transaction (Month/Day/Year) 02/04/2020) Covance Drug		below)	·
(Street) BURLIN (City)	IGTON N	State)	27215 (Zip)	- David		Line)								ne) X	Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transa Date (Month/E				action	ar)	2A. Deem Execution	A. Deemed recution Date,		3. 4. Transaction D		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			Ť	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
										Code V		Amount	(A) o (D)	Price	,	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)
		-	Fable II - [or Ben ole secu			wned		,	·	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day/	Date, T	I. Fransa Code (I		5. Number of		6. Date Exercisal Expiration Date (Month/Day/Year		te	le and	7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price o Derivative Security (Instr. 5)		9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ve es ally ig d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exer	: cisable	Ex Da	piration tte	Title	Amour or Number of Shares	er					
Restricted Stock Unit	(1)	02/04/2020			A		1,680			(2)		(2)	Common Stock	1,680)	\$0	11,534	(3)	D	
Non- qualified	\$182.51	02/04/2020			A		7,300		02/04	4/2021 ⁽⁵⁾	02	/03/2030	Common	7,300		\$0	7,300		D	

Explanation of Responses:

Options⁽⁴⁾

- 1. Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- $2.\ The\ Restricted\ Stock\ Units\ vest\ in\ three\ equal\ annual\ installments\ beginning\ on\ February\ 4,\ 2021.$
- ${\it 3. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.}\\$
- 4. Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- 5. The option vests in three equal annual installments beginning on the date reflected in this column.

/s/ Sandra van der Vaart,

Attorney-in-Fact for Paul R. 02/06/2020

Kirchgraber

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.